Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

Core Insights - Lexicon Pharmaceuticals announced positive results from a post hoc analysis of sotagliflozin, indicating improved glycemic control in type 1 diabetes patients with normal and mildly reduced kidney function after one year [1][2] Group 1: Clinical Study Results - The post hoc analysis utilized pooled data from two 52-week, placebo-controlled trials, showing that both 200 mg and 400 mg doses of sotagliflozin significantly decreased HbA1c, body weight, systolic blood pressure, and total insulin use compared to placebo in patients with CKD Class 1 and 2 [2][3] - Improvements in efficacy measures were less pronounced in patients with CKD Class 3A, but sotagliflozin still reduced events of blood glucose ≤55 mg/dL across all kidney function categories [3] Group 2: Future Developments - Lexicon is on track to resubmit the New Drug Application (NDA) for ZYNQUISTA (sotagliflozin) in 2026, based on FDA feedback and additional clinical data from the STENO1 study [4] - The STENO1 study is an investigator-initiated study conducted by the Steno Diabetes Center in Denmark, focusing on sotagliflozin and other agents [4] Group 3: About Sotagliflozin - Sotagliflozin is an oral dual inhibitor of SGLT1 and SGLT2, responsible for glucose regulation, and has been studied in various patient populations, including approximately 20,000 patients across conditions like heart failure and chronic kidney disease [5] - The drug is also under investigation for hypertrophic cardiomyopathy (HCM) [5] Group 4: Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, with a pipeline in neuropathic pain, HCM, obesity, metabolic disorders, and other cardiometabolic indications [6]